Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 98 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carboxymethylcellulose Clear all
Completed Not applicable Interventional Results available

Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation

NCT02711995
View directory record Official record
Conditions
Essential Tremor
Interventions
RenuGel, Botulinum Toxin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Early Phase 1 Interventional

MUC1 Vaccine for Triple-negative Breast Cancer

NCT00986609
View directory record Official record
Conditions
Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Other
Lead sponsor
Joseph Baar, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 19, 2026, 1:37 AM EDT
Terminated Not applicable Interventional Results available

A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers

NCT03903692
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Marine polysaccharide dressing, Carboxymethylcellulose dressing
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Fresno, California • Selma, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

NCT01079741
View directory record Official record
Conditions
Melanoma
Interventions
NY-ESO-1 protein; Poly-ICLC; Montanide
Biological
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 2Phase 3 Interventional

A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop

NCT00243711
View directory record Official record
Conditions
Dry Eye
Interventions
Carboxymethylcellulose sodium and Glycerin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warrensburg, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 4 Interventional

Pediatric Dysphagia Outcomes After Injection Laryngoplasty for Type I Laryngeal Cleft

NCT01507207
View directory record Official record
Conditions
Dysphagia, Aspiration, Quality of Life
Interventions
Injection laryngoplasty
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

NCT03262103
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
Biological · Procedure
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 19, 2026, 1:37 AM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare a New Eye Drop Formulation With Refresh Contacts®

NCT01844388
View directory record Official record
Conditions
Contact Lens Lubrication
Interventions
carboxymethylcellulose based eye drop formula, carboxymethylcellulose sodium based eye drop solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Bloomington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 19, 2026, 1:37 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

NCT05249114
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Cabozantinib, Lu-177
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 1:37 AM EDT
Recruiting Phase 2 Interventional

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Autologous alpha-DC1/TBVA vaccine, Cabozantinib
Biological · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

NCT00514852
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Bisphenol A Controlled Exposure Study

NCT01573429
View directory record Official record
Conditions
Healthy Volunteers
Interventions
deuterated-Bisphenol A (d-BPA)
Other
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
25 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults

NCT03895749
View directory record Official record
Conditions
Hypertension
Interventions
NEO40 Daily
Dietary Supplement
Lead sponsor
Hypertension Institute, Nashville
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

NCT03054506
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
CSP01, Carboxymethylcellulose (CMC), Placebo
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
22 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

NCT00950248
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Idebenone, placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Effectiveness of a Marketed Denture Adhesive in Real-World Setting

NCT07273149
View directory record Official record
Conditions
Denture Retention
Interventions
Poligrip Power Max Hold + Seal
Device
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

NCT04302896
View directory record Official record
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 19, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01834248
View directory record Official record
Conditions
Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis, Poly ICLC
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 19, 2026, 1:37 AM EDT